SEQUENT
Sequent Scientific Limited (SEQUENT) Stock Analysis
Sequent Scientific Limited is a global animal healthcare company manufacturing veterinary APIs and formulations. It supplies active ingredients and finished products to animal health innovators worldwide. The company focuses on regulated veterinary pharmaceutical markets. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹201.20
+1.56% 1W | +26.20% 52W
Market Cap
8.8k CR
P/E Ratio
123.4
52W High
₹257.9
52W Low
₹117.3
Div. Yield
0%
Beta
1
50 DMA
₹208.7
200 DMA
₹193.4
Profit Margin
2.5%
Inst. Own.
7.4%
📊 CONSOLIDATION
📊 CONSOLIDATION
Could not load P&L data for SEQUENT.
SEQUENT
Holdings Analysis
Key strengths & risk signals
55
Overall
41
Fundamental
69
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (201.2) above 200-day but below 50-day.
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (208.7) is above 200-day average (193.4) - positive signal.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 733,182 vs down days: 586,476. Ratio: 1.25x
GOOD YEAR! Stock gained 26.2% in the last year.
Fundamental & Technical Analysis
55Overall
41Fundamental
69Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.1% (SLOW, 5/15). Profit CAGR: -18.9% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 2.5% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 38.0% public ownership - moderate retail influence.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (208.7) is above 200-day average (193.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (201.2) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATION
52W Performance
8/10
GOOD YEAR! Stock gained 26.2% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 733,182 vs down days: 586,476. Ratio: 1.25x
RSI
3/5
NEUTRAL! RSI at 51.6 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 59.7% of 52W range - neutral zone.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 1.6% (1 week), 4.5% (1 month), -9.3% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| PGHL | ₹5,232.50 | 24.3 | 24.9% | 8.2% | 19.3% | -15.7% | 76 | BREAKOUT | +45.3% | +1.7% | +7.4% | -1.8% |
| SUVEN | ₹285.40 | – | – | -19.3% | – | +44.2% | 52 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| AARTIPHARM | ₹867.60 | 36.9 | 10.4% | -2.6% | -3.3% | +7.1% | 54 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
| STAR | ₹1,084.80 | 16.3 | 12.3% | 8.7% | – | +37.8% | 68 | BREAKDOWN | +57.5% | +23.6% | +13.0% | -4.4% |
| VIYASH | ₹233.00 | 57 | 5.9% | 33.3% | – | +10.2% | 60 | BOUNCE FROM SUPPORT | +107.2% | +26.5% | +19.6% | +2.9% |
| BLISSGVS | ₹660.70 | 52.4 | 13.5% | 7.2% | 22.1% | +342.5% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹128.30 | 50.1 | 7.2% | 8.4% | 34.9% | +154.1% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
Data from TradeAlone · Updated daily
No news tagged for SEQUENT yet.
